NASDAQ$XNCR
Xencor Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Reported financial results for the fourth quarter and full year ended December 31, 2022.
Xencor reported a net loss of $12.0 million for the fourth quarter of 2022, compared to a net income of $73.1 million for the same period in 2021. Total revenue for the fourth quarter was $21.6 million, compared to $154.0 million for the same period in 2021. The company's cash, cash equivalents, receivables, and marketable debt securities totaled $613.5 million as of December 31, 2022.
- Advanced internal portfolio of XmAb drug candidates.
- Initiated Phase 1 studies for two novel T-cell engagers, XmAb819 and XmAb808.
- Expect to further expand wholly owned portfolio by initiating a Phase 1 study for XmAb662.
- Anticipate submitting an IND for XmAb541.
Headline financials
Revenue & EPS history
Xencor · Revenue · Quarterly
$21.6M
Forward guidance
Xencor expects to end 2023 with between $425 million and $475 million in cash, cash equivalents, receivables and marketable debt securities, and to have cash to fund research and development programs and operations through the end of 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
-0.1%
Avg return
Earnings day
-1.1%
Avg return
5 days after
-0.1%
Avg return
30 days after
48%
25 / 52 earnings
Positive
+11.3%
Q2 2018
Best reaction
-16.6%
Q2 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.2% | -0.5% | -8.4% | |
| Q4 2025 | +1.5% | +4.1% | -3.3% | |
| Q3 2025 | -2.4% | +3.5% | +20.4% | |
| Q1 2025 | +0.2% | -4.6% | +12.3% | |
| Q3 2024 | +7.7% | +8.3% | +17.8% | |
| Q2 2024 | -6.9% | -16.4% | -13.3% | |
| Q1 2024 | -5.0% | -13.9% | -8.1% | |
| Q4 2023 | -11.9% | -7.9% | -14.5% | |
| Q3 2023 | -6.3% | -7.3% | +9.8% | |
| Q2 2023 | +2.8% | +1.4% | -4.6% | |
| Q1 2023 | -2.2% | -2.4% | -1.6% | |
| Q4 2022 | -3.2% | -6.1% | -18.3% | |
| Q3 2022 | +8.6% | +9.0% | +9.9% | |
| Q2 2022 | +2.3% | +1.4% | -8.5% | |
| Q1 2022 | -1.0% | -2.5% | -16.7% | |
| Q4 2021 | +1.3% | -2.4% | -12.3% | |
| Q3 2021 | -7.0% | -6.4% | -13.3% | |
| Q2 2021 | +2.9% | -2.3% | +7.8% | |
| Q1 2021 | -2.4% | -6.3% | -10.4% | |
| Q4 2020 | -1.3% | +0.3% | -10.8% | |
| Q3 2020 | -8.7% | -3.9% | -5.7% | |
| Q2 2020 | -3.2% | +1.0% | +6.6% | |
| Q1 2020 | +7.1% | +7.3% | -3.2% | |
| Q4 2019 | -8.8% | -7.6% | -18.2% | |
| Q3 2019 | -1.0% | -1.0% | +20.9% | |
| Q2 2019 | -16.6% | -15.6% | -18.9% | |
| Q1 2019 | +10.7% | +4.9% | -3.5% | |
| Q4 2018 | -3.1% | -0.8% | +1.3% | |
| Q3 2018 | +6.2% | -0.3% | +3.7% | |
| Q2 2018 | +11.3% | +10.0% | +10.1% | |
| Q1 2018 | -2.5% | +4.4% | +38.4% | |
| Q4 2017 | +4.8% | +0.9% | +2.6% | |
| Q3 2017 | +2.1% | +4.6% | +10.7% | |
| Q2 2017 | +4.7% | -3.9% | -1.9% | |
| Q1 2017 | -6.8% | -6.3% | -12.0% | |
| Q4 2016 | +7.6% | +5.5% | -5.6% | |
| Q3 2016 | -11.0% | -4.7% | +24.9% | |
| Q2 2016 | +9.4% | +16.0% | +10.7% | |
| Q1 2016 | -2.9% | — | — | |
| Q4 2015 | +11.2% | — | — | |
| Q3 2015 | +4.6% | — | — | |
| Q2 2015 | -2.2% | — | — | |
| Q1 2015 | -5.5% | — | — | |
| Q4 2012 | +1.8% | — | — | |
| Q4 2014 | -0.9% | — | — | |
| Q3 2014 | +3.6% | — | — | |
| Q3 2013 | +3.6% | — | — | |
| Q2 2013 | +1.7% | — | — | |
| Q2 2014 | +2.6% | — | — | |
| Q4 2013 | -1.6% | — | — | |
| Q1 2013 | -1.6% | — | — | |
| Q1 2014 | -2.3% | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro